<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01797302</url>
  </required_header>
  <id_info>
    <org_study_id>PRO12100034</org_study_id>
    <secondary_id>R01HL112985</secondary_id>
    <secondary_id>5R01HL112985-05</secondary_id>
    <nct_id>NCT01797302</nct_id>
  </id_info>
  <brief_title>Vitamin D and Vascular Health in Children</brief_title>
  <official_title>Vitamin D and Vascular Function in Obese Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Office of Dietary Supplements (ODS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, we will test the central hypothesis that enhancement of vitamin D status in
      obese and overweight children will improve their vascular health and their cardiovascular
      disease (CVD) and metabolic syndrome risk profile.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our primary objective is to determine, in obese and overweight children aged 10 to 18 years
      with vitamin D deficiency (defined as serum 25-hydroxyvitamin D &lt;20 ng/mL), the efficacy of
      enhanced vitamin D3 supplementation in improving vascular endothelial function, arterial
      stiffness, insulin sensitivity, and metabolic syndrome risk status; and to assess whether
      these effects are dose-dependent. As a secondary objective, we will examine the vitamin D
      supplementation-induced effect on adipokines and inflammatory markers relevant to CVD risk.
      In a double-masked, controlled trial, we will randomize 252 eligible children to receive
      either 600 IU (conventional supplementation), or 1000 IU or 2000 IU (enhanced
      supplementation) of vitamin D3 daily for 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">January 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>brachial artery flow-mediated dilation (FMD)</measure>
    <time_frame>6 months</time_frame>
    <description>measure of vascular endothelial function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pulse-wave velocity (PWV)</measure>
    <time_frame>6 months</time_frame>
    <description>measure of arterial stiffness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting glucose/fasting insulin ratio</measure>
    <time_frame>6 months</time_frame>
    <description>Homeostasis Model of Assessment - Insulin Resistance (HOMA-IR) as a surrogate estimate of insulin sensitivity</description>
  </secondary_outcome>
  <other_outcome>
    <measure>blood pressure, waist circumference, HDL cholesterol, triglycerides, and fasting blood glucose</measure>
    <time_frame>6 months</time_frame>
    <description>components of metabolic syndrome</description>
  </other_outcome>
  <other_outcome>
    <measure>inflammatory markers</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>adipokines</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>nitric oxide metabolites</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">252</enrollment>
  <condition>Obesity</condition>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>Vitamin D3 2000 IU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin D3 2000 IU tablet once daily by mouth for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D3 1000 IU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin D3 1000 IU tablet by mouth once daily for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D3 600 IU</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vitamin D3 600 IU tablet by mouth once daily for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Tablet form</description>
    <arm_group_label>Vitamin D3 2000 IU</arm_group_label>
    <arm_group_label>Vitamin D3 1000 IU</arm_group_label>
    <arm_group_label>Vitamin D3 600 IU</arm_group_label>
    <other_name>Cholecalciferol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible subjects will be 10 to 18 years of age;

          -  obese or overweight (BMI ≥85th %tile);

          -  otherwise healthy, and

          -  have a serum 25(OH)D concentration &lt;20 ng/mL

        Children taking multivitamins should be able to hold off their multivitamins during the
        course of the study.

        Exclusion Criteria:

        Children will be excluded if they

          -  (a) have hepatic or renal disease, metabolic rickets, malabsorptive disorders, primary
             hyperparathyroidism, hyperthyroidism, or other chronic disorders that could affect
             vitamin D metabolism;

          -  (b) are receiving treatment with anticonvulsants, systemic glucocorticoids,
             pharmacologic doses of vitamin D (≥1000 IU of vitamin D2 or D3 daily),
             antihypertensives, vasoactive drugs, antilipidemics, metformin, antipsychotics, or
             other oral insulin regulators;

          -  (c) have cholelithiasis or urolithiasis;

          -  (d) have type 1 or type 2 diabetes; or

          -  (e) have a condition or underlying abnormality that could compromise the safety of the
             subject.

        Post-menarchial girls with a positive pregnancy test at randomization, or subjects found
        during the screening phase to have hypercalcemia (serum calcium &gt;10.8 mg/dL) or significant
        fasting hyperglycemia (fasting blood glucose ≥ 125 mg/dL) will also be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kumaravel Rajakumar, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh, Children's Hospital of Pittsburgh of UPMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Flora Olabopo, BS</last_name>
    <phone>412-692-8737</phone>
    <email>flora.olabopo@chp.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kumaravel Rajakumar, MD, MS</last_name>
    <phone>412-692-5415</phone>
    <email>kumaravel.rajakumar@chp.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Primary Care Center, Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kumaravel Rajakumar, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2013</study_first_submitted>
  <study_first_submitted_qc>February 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2013</study_first_posted>
  <last_update_submitted>February 2, 2018</last_update_submitted>
  <last_update_submitted_qc>February 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Kumaravel Rajakumar</investigator_full_name>
    <investigator_title>Associate Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Vitamin D Deficiency</keyword>
  <keyword>Vascular Function</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>metabolic syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

